retatrutide approval status eli lilly The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from still in Phase II trials. While early studies have shown promising weight-loss results, Eli Lilly retatrutide Phase 3

Such cardiometabolic risk factors, the most widely recognised of which include dyslipidaemia, hypertension and elevated plasma glucose, have been shown to promote the development of atherosclerotic cardiovascular disease (ASCVD)

Freezing reconstituted peptide is debated, but multiple freeze-thaw cycles definitely degrade quality

Wegovy, Ozempic, and Mounjaro were also prescribed frequently

Track blood glucose, blood pressure, lipid panels, and testosterone levels at baseline and weeks 4, 8, and 12

Declining estrogen levels are thought to be a major contributor to central abdominal fat

Dispose of used needles safely in a sharps container